Plasma N-terminal proANP predicted development of congestive heart failure in stable community heart disease patients, enabling early identification of those at risk for disease progression.
Key findingN-terminal proANP predicted incident CHF in stable community heart disease patients, with elevated levels identifying those who would progress from co
What the researchers found
N-terminal proANP predicted incident CHF in stable community heart disease patients, with elevated levels identifying those who would progress from compensated heart disease to symptomatic heart failure.
Why it matters
Relevant for natriuretic-peptides, cardiovascular, clinical-trials.
How the study worked
cohort study on natriuretic-peptides, cardiovascular.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability.
Scandinavian journal of clinical and laboratory investigation, 64(7), 619-28
Citation
Nielsen, O W; Rasmussen, V; Christensen, N J; Hansen, J F. (2004). Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability.. Scandinavian journal of clinical and laboratory investigation, 64(7), 619-28.